Details for Patent: 7,276,529

Title:	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione
Abstract:	Methods of treating, managing or preventing exercise-induced asthma are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
Inventor(s):	Muller; George W. (Bridgewater, NJ), Schafer; Peter H. (Sommerset, NJ), Rohane; Patricia E. W. (Florham Park, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Mar 28, 2006
Application Number:	11/392,846
Claims:	1. A method of treating exercise-induced asthma, which comprises administering to a patient in need of such treatment a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof, substantially free of its (-) enantiomer. 2. The method of claim 1, wherein the patient is administered with (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione having the formula: ##STR00002## 3. The method of claim 1, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione is administered as a pharmaceutically acceptable salt. 4. The method of claim 1, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione is administered as a pharmaceutically acceptable solvate. 5. The method of claim 4, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione is administered as a pharmaceutically acceptable hydrate. 6. The method of claim 1, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione or a pharmaceutically acceptable salt or solvate thereof is administered orally. 7. The method of claim 6, wherein the compound is administered in a dosage form of a tablet or a capsule. 8. The method of claim 1, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione or a pharmaceutically acceptable salt or solvate thereof is administered nasally. 9. The method of claim 8, wherein the compound is administered in a dosage form of an aerosol or a spray. 10. The method of claim 8, wherein the compound is administered via a metered dose inhaler. 11. The method of claim 1, wherein the therapeutically effective amount is from about 1 mg to about 1,000 mg per day. 12. The method of claim 11, wherein the therapeutically effective amount is from about 5 mg to about 500 mg per day. 13. The method of claim 12, wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day. 14. The method of claim 1, wherein the therapeutically effective amount is from about 0.01 mg to about 100 mg per kg of a body weight of the patient per day. 15. The method of claim 14, wherein the therapeutically effective amount is about 1 mg, 10 mg or 25 mg per kg of a body weight of the patient per day.